Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab177896-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$69.90
|
|
|
Ab177896-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$339.90
|
|
|
Ab177896-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$869.90
|
|
|
Ab177896-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,429.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Glenzocimab (anti-GP6) - Primary antibody, specific to GP6, >95%, high purity, Human IgG1, INHIBITOR of Platelet glycoprotein VI (GPVI) inhibitor |
|---|---|
| Synonyms | Glycoprotein 6 | GPVI |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Collagen receptor involved in collagen-induced platelet adhesion and activation. Plays a key role in platelet procoagulant activity and subsequent thrombin and fibrin formation. This procoagulant function may contribute to arterial and venous thrombus for |
| Host species | Human |
| Specificity | GP6 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Platelet glycoprotein VI (GPVI) inhibitor |
| Product Description |
Glenzocimab (anti-GP6) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab (anti-GP6) inhibits collagen-induced platelet aggregation. Glenzocimab (anti-GP6) has the potential for the research of acute ischemic stroke. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 48.29 kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 2101829-58-5 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Glenzocimab (anti-GP6) (Ab177896) - ELISA
Immobilized hu-GPVI-ECD-IEGRMD-hFc at 2.0 μg/mL can bind Glenzocimab (anti-GP6) (Ab177896) with the EC
₅₀
of 67.06 ng/mL.
Glenzocimab (anti-GP6) (Ab177896) - SEC
The purity of Glenzocimab (anti-GP6) (Ab177896) is more than 95% verified by HPLC.